newsfilter
← Latest News
Business Wire·

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

Tozorakimab showed clinically meaningful benefits across blood eosinophil thresholds Full results published in the New England Journal of Medicine and presented at the European Respiratory Society Congress